Invo Fertility, INC. (IVF) — 8-K Filings

All 8-K filings from Invo Fertility, INC.. Browse 41 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (41)

8-K Filing — Dec 17, 2025
INVO Fertility Files 8-K: Material Agreement, Equity Sales — Dec 5, 2025 Risk: medium
On December 2, 2025, INVO Fertility, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
8-K Filing — Dec 3, 2025
INVO Fertility Reports Unregistered Equity Sale — Oct 22, 2025 Risk: medium
On October 16, 2025, INVO Fertility, Inc. reported an unregistered sale of equity securities. The filing does not disclose the specific number of shares sold or
INVO Fertility Files 8-K on Equity Sale — Oct 10, 2025 Risk: medium
On October 6, 2025, INVO Fertility, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The company, formerly known as NAYA Bioscienc
INVO Fertility, Inc. Files 8-K with Material Agreement — Oct 3, 2025 Risk: medium
On September 30, 2025, INVO Fertility, Inc. entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Securities a
INVO Fertility, Inc. Files 8-K with Material Agreement — Sep 29, 2025 Risk: medium
On September 29, 2025, INVO Fertility, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
INVO Fertility, Inc. Files 8-K for Material Agreement — Sep 26, 2025 Risk: medium
On September 22, 2025, INVO Fertility, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to
INVO Fertility Reports Unregistered Equity Sale — Sep 12, 2025 Risk: medium
On September 8, 2025, INVO Fertility, Inc. reported an unregistered sale of equity securities. The filing does not disclose the specific number of shares sold,
INVO Fertility, Inc. Reports Change in Certifying Accountant — Sep 5, 2025 Risk: low
INVO Fertility, Inc. filed an 8-K on September 3, 2025, reporting changes in its certifying accountant. The company, formerly known as NAYA Biosciences, Inc. an
INVO Fertility Files 8-K: Material Agreements & Equity Updates — Aug 22, 2025 Risk: medium
On August 21, 2025, INVO Fertility, Inc. entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Securities and
INVO Fertility Files 8-K with Financials — Aug 15, 2025 Risk: low
On August 14, 2025, INVO Fertility, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as NAYA Biosciences, In
INVO Fertility Reports Unregistered Equity Sale — Aug 1, 2025 Risk: medium
On July 28, 2025, INVO Fertility, Inc. filed an 8-K report detailing an unregistered sale of equity securities. The company, formerly known as NAYA Biosciences,
INVO Fertility Files 8-K on Equity Sales and Shareholder Votes — Jul 23, 2025 Risk: medium
On July 17, 2025, INVO Fertility, Inc. reported on the unregistered sale of equity securities and the submission of matters to a vote of security holders. The c
INVO Fertility, Inc. Amends Articles of Incorporation — Jul 21, 2025 Risk: low
On July 17, 2025, INVO Fertility, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation. The company, formerly known as NAYA Bioscience
INVO Fertility Approves 1-for-20 Reverse Stock Split — Jul 10, 2025 Risk: medium
On July 9, 2025, INVO Fertility, Inc. announced that its Board of Directors approved a reverse stock split of its common stock at a ratio of 1-for-20. This acti
INVO Fertility Files 8-K: Material Agreement, Equity Sales — Jul 1, 2025 Risk: medium
On June 27, 2025, INVO Fertility, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and am
INVO Fertility Files 8-K on Security Holder Vote Matters — Jun 25, 2025 Risk: medium
On June 25, 2025, INVO Fertility, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as NAYA
INVO Fertility Completes NAYA Biosciences Asset Acquisition — Jun 6, 2025 Risk: medium
INVO Fertility, Inc. announced the completion of its acquisition of assets from NAYA Biosciences, Inc. on June 2, 2025. This strategic move aims to expand INVO
INVO Fertility Files 8-K: Agreements, Equity Sales, Officer Changes — May 30, 2025 Risk: medium
On May 23, 2025, INVO Fertility, Inc. filed an 8-K detailing several significant events. These include entering into a material definitive agreement, unregister
INVO Fertility Files 8-K on Financials — May 21, 2025 Risk: low
INVO Fertility, Inc. filed an 8-K on May 21, 2025, reporting on events as of May 20, 2025. The filing pertains to Results of Operations and Financial Condition,
INVO Fertility Faces Delisting Concerns — Apr 18, 2025 Risk: high
INVO Fertility, Inc. filed an 8-K on April 18, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly known
NAYA Biosciences Reports Shareholder Vote Matters — Apr 14, 2025 Risk: low
NAYA Biosciences, Inc. filed an 8-K on April 14, 2025, reporting on matters submitted to a vote of security holders on April 9, 2025. The filing details the com
NAYA Biosciences Faces Delisting Notice — Mar 31, 2025 Risk: high
NAYA Biosciences, Inc. filed an 8-K on March 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly kno
NAYA Biosciences Files 8-K with Corporate Updates — Mar 24, 2025 Risk: low
NAYA Biosciences, Inc. (formerly INVO Bioscience, Inc.) filed an 8-K on March 24, 2025, reporting events that occurred on March 18, 2025. The filing indicates c
NAYA Biosciences Files 8-K: Other Events & Exhibits — Mar 7, 2025 Risk: low
On March 7, 2025, NAYA Biosciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific mat
NAYA Biosciences Faces Delisting, Material Agreements — Jan 16, 2025 Risk: high
On January 10, 2025, NAYA Biosciences, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreemen
NAYA Biosciences Files 8-K — Nov 8, 2024 Risk: low
NAYA Biosciences, Inc. filed an 8-K on November 8, 2024, reporting other events and financial statements and exhibits. The report covers events as of November 4
INVO Bioscience Reports Material Agreements & Asset Changes — Oct 15, 2024 Risk: medium
INVO Bioscience, Inc. filed an 8-K on October 15, 2024, reporting several key events as of October 11, 2024. These include entering into a material definitive a
INVO Bioscience Enters Material Agreement, Incurs Financial Obligation — Oct 1, 2024 Risk: medium
INVO Bioscience, Inc. entered into a Material Definitive Agreement on September 25, 2024, which also created a direct financial obligation for the registrant. T
INVO Bioscience Faces Delisting Concerns, Restates Financials — Sep 20, 2024 Risk: high
INVO Bioscience, Inc. filed an 8-K on September 20, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company also disclo
INVO Bioscience Files 8-K for Equity Sale — Sep 18, 2024 Risk: medium
On September 12, 2024, INVO Bioscience, Inc. entered into a material definitive agreement related to the unregistered sale of equity securities. The company, in
INVO Bioscience Enters Material Definitive Agreement — Jul 5, 2024 Risk: medium
On June 28, 2024, INVO Bioscience, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details on the nature of the agreemen
INVO Bioscience Faces Nasdaq Delisting Warning — Jun 20, 2024 Risk: high
INVO Bioscience, Inc. announced on June 13, 2024, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing requirem
INVO Bioscience Files 8-K: Material Agreement & Equity Sales — May 6, 2024 Risk: medium
INVO Bioscience, Inc. announced on May 1, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity
INVO Bioscience Faces Delisting and Agreement Termination — Apr 19, 2024 Risk: high
INVO Bioscience, Inc. announced on April 17, 2024, the termination of a material definitive agreement and received a notice of delisting or failure to satisfy c
INVO Bioscience Files 8-K: Agreements, Debt, and Equity Sales — Apr 11, 2024 Risk: medium
On April 5, 2024, INVO Bioscience, Inc. entered into a material definitive agreement, likely related to financing or operations, as indicated by the filing of a
INVO Bioscience Files 8-K: Material Agreement & Equity Sales — Apr 1, 2024 Risk: medium
On March 27, 2024, INVO Bioscience, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company
INVO Bioscience Secures $1.5M Loan — Mar 1, 2024 Risk: medium
On February 26, 2024, INVO Bioscience, Inc. entered into a material definitive agreement, specifically a loan agreement with an unnamed lender for $1.5 million.
INVO Bioscience Files 8-K on Jan 19 Event; Nasdaq Listing Confirmed — Feb 1, 2024
INVO Bioscience, Inc. filed an 8-K on February 1, 2024, reporting an "Other Event" that occurred on January 19, 2024. This filing primarily serves to update adm
INVO Bioscience Reports Unregistered Equity Sales, Material Agreement — Jan 3, 2024
INVO Bioscience, Inc. (INVO) filed an 8-K on January 3, 2024, reporting events from December 27, 2023, concerning an "Entry into a Material Definitive Agreement

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX